1. Emerging norovirus GII.4 Sydney[P31] causing acute gastroenteritis outbreak in children in Japan, during COVID-19, 2021
- Author
-
Ngan Thi Kim Pham, Shuichi Nishimura, Yuko Shimizu-Onda, Quang Duy Trinh, Shihoko Komine-Aizawa, Pattara Khamrin, Shoko Okitsu, Shintaro Sato, Takeshi Kobayashi, Niwat Maneekarn, Satoshi Hayakawa, and Hiroshi Ushijima
- Subjects
Microbiology (medical) ,Genotype ,Norovirus ,COVID-19 ,Gastroenteritis ,Feces ,Infectious Diseases ,Japan ,Child, Preschool ,Humans ,Pharmacology (medical) ,Child ,Pandemics ,Phylogeny ,Caliciviridae Infections - Abstract
Norovirus (NoV) is the most common agent causing outbreaks and sporadic cases of acute gastroenteritis among all ages, especially children under 5 years old. During the coronavirus disease 2019 (COVID-19) pandemic, NoV infection has decreased drastically in Japan due to school closures and no outbreak related to NoV infection had been reported.In mid-September 2021, NoV outbreak occurred in kindergarten and nursery schools in Maizuru, Kyoto prefecture, Japan. Twenty-six stool samples collected from patients who were diagnosed of NoV gastroenteritis from the outbreak by an immunochromatographic (IC) kit at a pediatric outpatient clinic in Maizuru city during 3 weeks from September 13 to October 8, 2021 were examined for the presence of NoV GII by reverse transcriptase-polymerase chain reaction (RT-PCR), genome sequencing, and phylogenetic analysis.All 26 samples were confirmed positive to NoV GII and their genotypes were identified as GII.4 Sydney[P31]. The amino acid substitutions in open reading frame1 (ORF1) and ORF2 genes were found when compared with previously detected sporadic NoV GII.4 Sydney[P31] strains isolated in Japan. The clinical characterization of infected children was described. Most of the children were mild cases and vomiting was the most frequent clinical symptom.This study reported a recent emergence of NoV GII.4 Sydney[P31] causing acute gastroenteritis outbreak in children in Japan during the COVID-19 pandemic and suggests a need for further monitoring of NoV GII.4 variants.
- Published
- 2022